| Identification | Back Directory | [Name]
BRD1652
(BRD 1652) | [CAS]
1597438-92-0 | [Synonyms]
BRD1652
BRD1652
(BRD 1652)
5H-Pyrazolo[3,4-b]quinolin-5-one, 1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-3-(trifluoromethyl)-, (4S)- | [Molecular Formula]
C20H20F3N3O | [MOL File]
1597438-92-0.mol | [Molecular Weight]
375.39 |
| Hazard Information | Back Directory | [Description]
BRD1652 is a highly selective and potent GSK3 inhibitor. BRD1652 demonstrates in vivo efficacy in a dopaminergic signaling paradigm modeling mood-related disorders. The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3). | [Uses]
BRD1652 is a highly selective GSK3 inhibitor. BRD1652 can be used in the study of emotion-related diseases[1]. | [in vivo]
BRD1652 (30 mg/kg intraperitoneal injection, single dose) can reduce amphetamine-induced hyperactivity disorder (AIH) in mice[1].
| [References]
[1] Wagner FF, et al. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. ACS Chem Biol. 2016 Jul 15;11(7):1952-63. DOI:10.1021/acschembio.6b00306 |
|
|